full comment requir non-u analyst conflict disclosur
pleas click link
new york mellon
assembl next-gen cf pipelin worth watch initi outperform
sell-off creat favor risk/reward momentum rais ep pt
enter busi heplisav-b launch asco data
recap model updat
strong growth larg bake
navig challeng environ top tier portfolio maintain top pick
increas reinvest gener quick return
first glanc energi retail result in-lin solar continu drag
continu win design ip busi samsung
earn preview debut quarter right fairway
straightforward path dsuvia resubmiss expect catalyst-heavi
takeaway post-aaaai allergist kol call transcript
deep dive gener capit alloc path net neutral
result outlook highlight share gain transform busi model
acquir esrx
highlight analyst day
earn refresh confer call chat manag
airasia portfolio add predict strong outlook summari
valu remain pipelin expect subsi turnaround
solid start
expect preliminari guidanc reiter
hit growth reset button
investor day focu drive revenu growth
price prior day market close estimate unless otherwis note
intern count trend
busi jet market final
dell-emc result
takeaway aao still
driver seat
 of daili summari
polici trend like pressur snf
e-commerce air
updat
higher corn/wheat price posit higher soybean stock offset
impact stx
compani present mime sap top
geopolit oil natur ga gold
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
valu usd unless otherwis note
valu usd unless otherwis note
assembl next-gen cf pipelin worth watch initi outperform
initi outperform rate price target believ pti suit
cystic fibrosi cf asset shown promis preclin signal earli clinic
promis despit high competit bar see multipl shot goal
success readout advanc pti potenti captur subset
larg cf market
preclin data suggest potenti activ multipl possibl role
cf asset futur paradigm
earli data indic possibl clinic signal stock upside/downsid skew
favor addit near-term result could support efficaci
competit import headwind market opportun could
meaning compani pti size asset success
sell-off creat favor risk/reward momentum rais ep
despit elev comp expect sell-off appear overdon given
still strong msd comp guid vs current hsd run rate ahead consensu
outlook see dream ep tabl brand
maintain momentum gross margin recov model see tax
boost rais ep pt
despit street comp estim msd comp outlook match
elev expect heel posit hsd comment
compar get harder feb ly flat slightli neg vs mar/apr
msd total see room msd comp guid given men digit
aeri momentum top posit store environ conserv
model comp
direct contribut comp channel penetr
dd gain go forward suggest comp lift posit store upsid
end callout posit store traffic qtd
suggest balanc comp composit go forward
guid expans pressur despit
bp gm miss street expect leverag
awar inventori increas unit model
expans intend watch promot clearanc level
rais estim pt ep move tax rate
includ ep move
rais target base updat ep
enter busi heplisav-b launch asco data
expect present initi head/neck updat melanoma pt data
abstract addit on-going launch heplisav-b
fulli initi expect gradual first see
stabl out-year sale set valuat floor thu littl credit given
io platform see share appreci addit data
compani end cash includ rais part
atm broker arrang rais addit
follow posit vote cdc vaccin committe acip
discuss confer compani abl fulli engag
hospit begun commerci launch heplisav-b
plan present orr data cohort head neck
patient durabl data melanoma cohort on-going
ph ii studi april
recap model updat
inxn report strong financi result introduc guidanc mid-teen
revenu ebitda growth support continu strong demand healthi
macroeconom backdrop increas price target result
revis outlook
inxn report better-than-expect financi result consolid revenu
increas y/i organ fx-adjust basi adjust
ebitda increas y/i manag introduc guidanc
suggest anoth year mid-teen revenu ebitda growth mid-
point support continu strong demand healthi macroeconom
backdrop new revenue/ebitda estim
estim increas price target
result revis outlook
valu usd unless otherwis note
market data usd financi data eur dividend paid
strong growth larg bake
valu usd unless otherwis note
valu usd unless otherwis note
view nep best-in-class yieldco albeit come substanti premium
admittedli weak sector potenti sale canadian asset
interest develop capit recycl front npv
posit near-term accret seem challeng adjust ebitda
estim introduc estim includ canadian
expect nextera energi partner nep deliv consist growth thank
relationship sponsor outperform unlik
yieldco nep mean fund growth easi access
capit market asset could drop nep nextera
neer continu focu neer
develop despit less favor backdrop remain posit
outlook renew cost come renew becom
nep determin partli due tax reform would better monet
canadian portfolio re-deploy -base asset perhap form
third-parti drop-down neer
transact like would posit npv perspect think
accret cafd front challeng near-term howev
would surpris us nep abl structur sale make
ebitda estim go
introduc ebitda estim
continu believ nep need substanti drop-down
neer order meet growth target long-term howev
think de-consolid nep balanc sheet could increas
amount drop-down credit rate longer
navig challeng environ top tier portfolio maintain top
remain top pick compani appear well posit deliv
ffo/shar growth via top tier portfolio extern growth platform share
pressur due broader industri concern expect
separ peer high qualiti balanc sheet give flexibl
continu repurchas share time disloc
manag indic leas spread new shop space avoid
nois anchor space in-lin prior year
capital-expenditure percent noi histor rang
manag indic leas econom in-lin prior year
compar space look invest capit leas
remain hard leas space
net debt ebitda company-defin total
debt fix interest rate recent refinanc averag matur
increas nine year consolid debt given stabil
balanc sheet major matur good
posit execut share repurchas plan
subsequ year end retir secur debt unsecur debt
weight averag rate issuanc million unsecur
valu usd unless otherwis note
market data cad financi data usd dividend paid
increas reinvest gener quick return
investor spook y/i gross margin contract
weaker margin outlook howev mostli due tax reinvest
acceler invest remov c-store contribut id sale growth
recoveri remain track believ benefit implement
vendor late/incomplet deliveri penalti price negoti could off-set
on-going price invest reiter outperform lower price target
report adjust ep revenu consensu
ident sale ex fuel con
includ fuel gross margin y/i lighter
consensu expect forward-year guidanc impli margin
contract howev mostli due tax reinvest acceler
invest remov c-store contribut id sale growth recoveri
remain track believ benefit implement vendor
late/incomplet deliveri penalti price negoti could off-set on-going
price invest kr guid id sale growth ex fuel
adjust ep fy tax rate although guidanc assum
close c-store sale neutral transact addit
reinvest two-third tax save higher origin estim
one-third id sale ex fuel unchang ebit margin
reduc y/i contract ep estim
multi-year ebit outlook
unchang despit spend tax benefit return invest
appear swift reiter outperform lower price target
anticip reinvest
first glanc energi retail result in-lin solar continu drag
expect share trade higher depress level head
quarter believ investor spook concern regard liquid
distribut sustain releas result believ
compani liquid posit suffici million leverag
conserv ebitda forecast believ pay-out
ratio remain rang unit remain depress fulli
expect compani repurchas unit ncib
million fall short estim consensu million
consensu rang million varianc due million
ebitda contribut solar divis compar estim
million quarter compani lost rce acquisit
compar gain rce net attrit disappoint
manag highlight driven non renew municip
exposur viridian legal settlement consist reserv last month
preliminari approv million class action lawsuit settlement
valu usd unless otherwis note
valu usd unless otherwis note
regard viridian previous own criu reach manag
made previou arrang cap exposur million
confer call friday march et dial-in number
expect investor focu custom attrit gross
margin trend opportun addit colour manag
approach ncib
complianc design secur healthcar meteorolog iii trust secur
cloud revenu multi-cloud/port ai secur
system stabl adjust product cycl see opportun
expand ts cloud gb margin blockchain
current on-going engag custom across food financi
servic ship vertic quantum comput compani
work qubit system reiter long-term target low-single-digit
continu win design ip busi samsung
top pick announc collabor samsung
foundri develop design ware foundat ip samsung
power finfet process technolog importantli logic librari
embed memori schedul avail addit win
ip side think increas confid ip revenu growth
particularli given busi grew last year think doubl digit
fair net net view announc slight posit
given releas date reiter top pick rate share
given confid manag execut top-lin growth
earn preview debut quarter right fairway
attribut outperform-r gate share trade launch price
mostli jitteri investor wait first assurances/commentari
compani sinc ipo confid manag geared-up
requisit inline/modest beat debut quarterli earn report after-
market-clos like busi model expect pattern
promis deliv
valu usd unless otherwis note
valu usd unless otherwis note
expect unev debut quarter organ growth
million adjust ebitda tuesday gate host debut
earn call public compani despit recent share under-perform
remain posit global leader premium brand engin belt
hose given healthi macro backdrop take under-perform
least partli attribut typic nervous absenc
recent manag commentary/reassur given quiet period
time shortli ipo recent market volatil also like
contribut jitter untest name like gate key
metric expect sale million adjust ebitda million
well organ growth modest adjust ebitda margin contract
bp gate set guidanc rang key oper target
thesi stock remain see initi differenti
approach valuat still suggest ampl upsid share
reiter outperform rate
straightforward path dsuvia resubmiss expect catalyst-heavi
report focu feedback follow type meet
fda review meet minut dsuvia follow call
continu see path refil rel straightforward human factor
studi like complet april addit trial need resubmit
approv anticip year-end chang outlook/target
zalviso refil track submit focu dsuvianot
surpris fda commun expect adcom expect
occur ahead approv also complet human
factor studi next month resubmit nda discuss
confer look stagger fda review well launch
continu see attract opportun eu effort
partner grunenth continu show progress see read-through
dsuvia type meet zalviso stagger time allow
focu launch separ
sever catalyst come month keep news flow name
remain track emea approv dsuvia known dzuveo ex-u
submit end march respons chmp decis
asid human factor studi data compil need
resubmiss catalyst includ potenti adcom dsuvia late
summer well zalviso refil continu believ could see
addit ex-u partnership see dzuveo approv expect
focu shift
takeaway post-aaaai allergist kol call transcript
valu usd unless otherwis note
valu usd unless otherwis note
conduct kol call discuss palisad data present
aaaai confer overal kol came away aaaai confer
impress efficaci safeti unexpectedli lower vs
histor oit trial saw foundat futur combo
biolog howev academ center-bas kol cautiou toward roll-
within privat practic set note potenti
requir addit staff physic space key takeaway pleas
see transcript pg onward detail
conduct kol call discuss palisad data present
aaaai confer overal kol came away aaaai confer
impress efficaci safeti unexpectedli lower vs
histor oit trial saw foundat futur combo
biolog howev academ center-bas kol cautiou toward
roll-out within privat practic set note
potenti requir addit staff physic space key takeaway
pleas see transcript pg onward detail
deep dive gener capit alloc path net
think solid net cash balanc result meaning
step-up capit alloc next quarter
need investor hyper fixat iphon
 cycl adopt trend think key posit resili
appetit deal benefit current tax reform expect
return much on-going gener back sharehold addit
expect provid roadmap intend return
net cash hand sharehold report march-qtr result
multipl possibl think like scenario maintain
mix buy-back dividend keep cash possibl deal
baselin assumpt annual grow mid-singl digit
util buyback dividend impli yield get
vs current could target increment annual
buyback balanc sheet cash impli total share reduct next
year could share share reduct total annual net/
net believ stock continu outperform market driven
strong gener abil outsiz capit alloc grow io
instal base gener sustain recur growth maintain op
capit market day articul strong case stand-alon
compani addit formal increment cost save plan
note track plan thank better raw continu
believ present attract fundament risk-reward signific upsid
valu usd unless otherwis note
reiter ebitda guidanc
refinish distributor de-stock rear-view mirror
isol one supplier industri sale under-penetr
market opportun particularli china repres
global industri coat consumpt oem benefit share
gain increas car park per capit market growth particularli asia
final commerci less share asia
market moreov global market non-truck remain
signific opportun
track ahead plan manag note thu far januari
februari track plan attribut conserv
budget raw headwind growth
introduc necessarili new
manag past call addit cost save
opportun post initi call increment
cost save four-year period
 pipelin robust like continu bolt-on deal
target smaller player look sell
rise rate environ manag believ industri see one two
larg consolid industri believ continu
result outlook highlight share gain transform busi
 freight cost pressur guidanc consensu suggest
flow tax save provid nice sigh relief comp
out-performance especi easi compar outlook on-going share gain
 margin expans equat high teen organ ep growth help
reviv confid stock
updat thought estim post earn
valu usd unless otherwis note
acquir esrx
posit deal esrx view sale good outcom
esrx sharehold consist view vertic integr
healthcar servic space leav pt evalu deal structur
ci share price potenti bidder emerg
need know express script announc deal ci
acquir esrx cash share ci stock view deal
valu usd unless otherwis note
valu usd unless otherwis note
posit believ good outcom esrx sharehold maintain
outperform rate impli return deal price potenti
bidder
highlight analyst day
analyst day larg focus around opportun hybrid cloud softwar
secur addit disclosur around softwar system servic
